单侧腹部皮瓣乳房再造前应提供乳腺癌易感基因检测
BACKGROUND: Pathogenic mutations have been identified in approximately 10 percent of patients who present with breast cancer.…
要点
- 符合NCCN基因检测指南的患者中仅55.9%接受了检测。
- 平均随访5.8年,3例(1.9%)检出致病突变并接受对侧手术。
核心结论
- 在单侧腹部皮瓣乳房再造前为所有患者提供基因检测具有成本效益。
研究设计与样本
- 回顾性队列研究,纳入2007至2016年Brigham and Women's Hospital/Dana-Farber Cancer Institute单侧腹部游离皮瓣乳房再造患者160例,平均随访5.8年。
主要发现
- 160例中3例(1.9%)完成再造后接受对侧手术,其中2例为BRCA2突变、1例为ATM突变。
关键数值与推荐
- 致病突变检出3例(1.9%,3/160),包括BRCA2 2例和ATM 1例。
临床怎么用
- 在单侧腹部皮瓣乳房再造前应评估并提供基因检测,避免供区一次性使用后才发现致病突变。
局限性
- 回顾性设计,随访时间相对较短(平均5.8年)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pathogenic mutations have been identified in approximately 10 percent of patients who present with breast cancer. Notably, failure to identify deleterious genetic mutations has particular implications for patients undergoing abdominally based breast reconstruction, as the donor site can be used only once. The authors sought to determine: (1) how many patients underwent genetic testing before unilateral abdominally based free flap breast reconstruction; (2) how often deleterious mutations were detected after abdominally based free flap breast reconstruction; and (3) the cost-effectiveness of expanding genetic testing in this patient population. METHODS: The authors retrospectively identified all patients who underwent unilateral abdominally based free flap breast reconstruction at Brigham and Women's Hospital/Dana-Farber Cancer Institute between 2007 and 2016. Chart review was performed to collect relevant demographic and clinical data. Relevant hospital financial data were obtained. RESULTS: Of the 713 who underwent free flap breast reconstruction, 160 patients met inclusion criteria, and mean follow-up was 5.8 years. Three patients (1.9 percent of 160) underwent contralateral surgery after completing reconstruction, two of whom had BRCA2 and one with ATM mutation. One hundred eleven patients met National Comprehensive Cancer Network guidelines for genetic testing, but of those only 55.9 percent (62 patients) were tested. Financial data revealed that testing every patient in the cohort would result in a net savings of $262,000. CONCLUSIONS: During a relatively short follow-up period, a small percentage of patients were diagnosed with pathogenic mutations and underwent contralateral mastectomy and reconstruction. However, because of the costliness of surgery and the decreased cost of genetic testing, it is cost-effective to test every patient before unilateral abdominally based free flap breast reconstruction.
引用
- Dayan E, Chittenden A, Garber JE, et al. Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction. Plast Reconstr Surg. 2019. PMID: 31246791. doi:10.1097/PRS.0000000000005693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。